Literature DB >> 12297603

Cataract occurrence with antipsychotic drugs.

Sajida Shahzad1, Mohammad-Irfan Suleman, Hasan Shahab, Iourii Mazour, Amanpreet Kaur, Peter Rudzinskiy, Steven Lippmann.   

Abstract

Chlorpromazine and several other phenothiazine neuroleptic drugs appear to induce cataract formation. However, the newer generation of antipsychotic agents has shown no evidence of an etiologic relationship with cataract occurrence. Research did reveal cataract occurrence in dogs who received quetiapine, which prompted concern despite there being no known causal link between quetiapine and lens opacities in humans. Nevertheless, quetiapine's manufacturer issued formal recommendations for ophthalmological follow-up examinations with the use of this drug. Infrequent occurrences of cataract development have been documented in people taking olanzapine but, again, without established causative association; a similar situation is seen with ziprasidone. Periodic ocular examinations of the lens are suggested for patients prescribed long-term treatment with phenothiazines or quetiapine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297603     DOI: 10.1176/appi.psy.43.5.354

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  10 in total

1.  Side effects of atypical antipsychotics: a brief overview.

Authors:  Alp Uçok; Wolfgang Gaebel
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

Review 2.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

3.  Treatment of ophidism-induced bilateral canine cataract by extracapsular lens extraction and intraocular lens implantation.

Authors:  M Kibar; C Evereklioğlu; Z Doğan
Journal:  Iran J Vet Res       Date:  2014       Impact factor: 1.376

Review 4.  Adverse effects of atypical antipsychotics in the elderly: a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Salvatore De Fazio; Norma Marigliano; Guido Ferreri Ibbadu; Giovambattista De Sarro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  A well-being support program for patients with severe mental illness: a service evaluation.

Authors:  Donna Eldridge; Nicky Dawber; Richard Gray
Journal:  BMC Psychiatry       Date:  2011-03-21       Impact factor: 3.630

6.  The serious mental illness health improvement profile [HIP]: study protocol for a cluster randomised controlled trial.

Authors:  Jacquie White; Richard J Gray; Louise Swift; Garry R Barton; Martin Jones
Journal:  Trials       Date:  2011-07-04       Impact factor: 2.279

7.  Chlorpromazine induced cataract in a young patient with schizophrenia.

Authors:  Anjith Divakaran; Naren P Rao; Ganesan Venkatasubramanian; Rishikesh V Behere; Shivaram Varambally; Bangalore N Gangadhar
Journal:  Indian J Psychol Med       Date:  2010-01

8.  EPR spectroscopy of chlorpromazine-induced free radical formation in normal human melanocytes.

Authors:  Michał Otręba; Magdalena Zdybel; Barbara Pilawa; Artur Beberok; Dorota Wrześniok; Jakub Rok; Ewa Buszman
Journal:  Eur Biophys J       Date:  2015-05-16       Impact factor: 1.733

9.  An increase in phosphorylation and truncation of crystallin with the progression of cataracts.

Authors:  Hui-Ju Lin; Chien-Chen Lai; Shiuan-Yi Huang; Wei-Yi Hsu; Fuu-Jen Tsai
Journal:  Curr Ther Res Clin Exp       Date:  2013-06

10.  Risperidone-induced cataract in a young female.

Authors:  R Balamurugan; P C Gupta; H Kashyap; Jagat Ram
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.